Research Hub cuts Geratherm Medical price target to EUR 4, maintains buy rating
Reuters2026/08/28 12:19- Analyst research flagged weak H1 2026 trading at Geratherm, citing respiratory supply constraints, softer demand, order delays in the Middle East.
- Inkubator-Systems rebounded strongly; product-mix shift supported gross margin, keeping gross profit stable despite revenue pressure.
- Cost inflation pushed EBIT into loss; inventory build weighed on operating cash flow.
- Management issued no quantitative FY26 guidance; analysts cut target price to EUR 4 from EUR 4.5.
- BUY rating maintained, citing large cash reserves as downside protection while the group shifts toward a MedTech holding structure.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Robinhood Chain hits record $989 million in daily DEX volume as TVL grows
After 30 years, Japan’s 10-year government bond yield returns to 3%, breaking the major shackles of the “zero interest rate era”
Japan’s 10-year government bond yield briefly rose to 3% on Tuesday, marking the first time this has occurred in the 21st century. This milestone signals an important step in the normalization process for the country's bond market, after years of benchmark borrowing costs hovering around zero.
Cerebras (CBRS.US) builds a new 165-megawatt AI data center in Finland, accelerating its computing power expansion in Europe
Cerebras Systems announced on Tuesday the establishment of a new AI data center in Mikkeli, Finland.
Crypto prices
More
